TAK-733 (69, CAS 1035555-63-5) is a compound developed and patented by Takeda Pharmaceutical Company in 2007 [115] as an inhibitor of MEK1 and MEK2 (MEK1/2) that was tested in clinical trials for advanced metastatic melanoma and advanced nonhematologic malignancies. This evidence concerns the gene MAP2K1 and metastatic melanoma.